spacer
home > ict > autumn 2017 > revolutionary potential
PUBLICATIONS
International Clinical Trials

Revolutionary Potential

For clinical research, the shift away from paper has been a
long and gradual process. Decades have now passed since
electronic data capture (EDC) was first implemented in a trial,
yet, to this day, some researchers remain beholden to paper
case report forms (CRFs) and databases. In fact, even those
who have switched are not fully electronic, as data is only
entered into the system after it is captured on a paper CRF at
the site level. In other words, while EDC has taken great strides
in modernising the operations of clinical data managers,
workflows at the site level are largely the same – as far as
data capture is concerned – as before the emergence of
eClinical technology.

This is one of the central reasons why the advent of eSource
technology – which allows data to be entered directly into
an electronic system and shared remotely with no paper
involved – represents a watershed moment for research.
eSource is largely seen as an improvement to timelines and
data integrity and, therefore, a boon for sponsors and CROs.
However, it is from these sites that these improvements
emanate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Novotny is founder and CEO at Medrio. He previously served as President of the EDC software company Ninaza before founding Medrio in 2005. Mike has 20 years of experience in research and software and holds a BA from Stanford University, US, and an MBA from Columbia University, US.

Nick O’Brien
is Marketing Copywriter at Medrio, where he writes the company blog as well as press releases and other copy. He has extensive experience writing for blogs and other media and holds a BA in English, with an emphasis on creative writing, from Kenyon College, US.
spacer
Mike Novotny
spacer
spacer
spacer
Nick O'Brien
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement